Sable Bio, a London-based AI startup focused on drug safety, has raised £2.7 million in seed funding to scale its platform that helps pharmaceutical companies identify safety risks earlier in drug discovery. The round was led by MMC Ventures, with participation from existing investors Episode 1 Ventures and Seedcamp.
Since its £1.5 million pre-seed in late 2023, the company has secured commercial agreements with multiple pharmaceutical companies, including three top-ten global pharma firms, alongside biotechs and investment groups, generating £0.4m in revenue in the past twelve months.
Unexpected toxicity remains the leading cause of clinical trial failures, costing the pharmaceutical industry billions every year. Target safety assessments rely on literature reviews, preclinical testing, and expert judgment, with manual processes struggling to keep pace with the growing volume of biomedical data available to drug discovery teams.
Sable’s AI-powered platform integrates diverse data sources into a unified safety assessment framework. Bespoke models extract safety-relevant information from millions of papers and reports, while causal inference methods separate true safety signals from noise. Scientists receive ranked insights designed to highlight critical concerns and enable earlier risk mitigation and planning.
The new capital will be used to expand the London-based team, accelerate product development, and integrate real-world evidence. The company is also seeking additional partnerships with biotech, pharmaceutical, and healthtech organisations looking to strengthen their target safety capabilities.
